Incentivize domestic manufacturing through grants and tax credits to reduce foreign reliance. Strengthen FDA oversight on imports while expediting reviews for qualified U.S. producers. Prioritize patient safety by favoring traceable, U.S.-made APIs in procurement and reimbursement policies. Standardize quality by collaborating with industry on robust testing protocols for potency and purity. Streamline approvals for domestic manufacturers to resolve supply shortages and quality gaps.
2026 · 3rd Quarter (July 1 - Sep 30)
SUMMIT WORKS USA
Filed by OSCAR POLICY GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 5, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- OSCAR POLICY GROUP, LLC
- Client
- SUMMIT WORKS USA
- Filing UUID
- fb838ba1-a560-445a-a708-0069687ced98
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.